Viva Biotech Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Viva Biotech Holdings' es Chen Cheney Mao , nombrado en Jul 2018, tiene una permanencia de 5.75 años. compensación anual total es CN¥2.76M, compuesta por 52.7% salario y 47.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 8.65% de las acciones de la empresa, por valor de HK$103.81M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 5 años, respectivamente.

Información clave

Chen Cheney Mao

Chief Executive Officer (CEO)

CN¥2.8m

Compensación total

Porcentaje del salario del CEO	52.7%
Permanencia del CEO	5.8yrs
Participación del CEO	8.7%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chen Cheney Mao en comparación con los beneficios de Viva Biotech Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CN¥116m
Sep 30 2023	n/a	n/a	-CN¥276m
Jun 30 2023	n/a	n/a	-CN¥436m
Mar 31 2023	n/a	n/a	-CN¥482m
Dec 31 2022	CN¥3m	CN¥1m	-CN¥528m
Sep 30 2022	n/a	n/a	-CN¥209m
Jun 30 2022	n/a	n/a	CN¥111m
Mar 31 2022	n/a	n/a	CN¥199m
Dec 31 2021	CN¥2m	CN¥1m	CN¥288m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥228m
Mar 31 2021	n/a	n/a	-CN¥79m
Dec 31 2020	CN¥1m	CN¥957k	-CN¥387m
Sep 30 2020	n/a	n/a	-CN¥349m
Jun 30 2020	n/a	n/a	-CN¥311m
Mar 31 2020	n/a	n/a	-CN¥23m
Dec 31 2019	CN¥1m	CN¥954k	CN¥266m

Compensación vs. Mercado: La compensación total ($USD381.52K) de Chen Cheney está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD357.52K).

Compensación vs. Ingresos: La compensación de Chen Cheney ha aumentado mientras la empresa no es rentable.

CEO

Chen Cheney Mao (60 yo)

5.8yrs

Permanencia

CN¥2,762,000

Compensación

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Chen Cheney Mao	Chairman & CEO	5.8yrs	CN¥2.76m	8.65% CN¥ 114.9m
Ying Wu	Executive VP & Executive Director	5.8yrs	CN¥3.07m	0.80% CN¥ 10.7m
Delin Ren	Executive Director	less than a year	CN¥3.72m	0.69% CN¥ 9.2m
Zheren Wang	Co-Chief Financial Officer	less than a year	sin datos	sin datos
Wei Xiong	Co-Chief Financial Officer	less than a year	sin datos	sin datos
Xueheng Cheng	Chief Technology Officer	4.8yrs	sin datos	sin datos
Zhixiong Ye	Chief Scientific Officer	5.8yrs	sin datos	sin datos
Han Dai	Chief Innovation Officer & Head of Viva BioInnovator	no data	sin datos	sin datos
Jianhua Cai	Senior Vice President	no data	sin datos	sin datos
Jianguo Ma	Senior VP & CEO of Langhua Pharmaceutical	no data	sin datos	sin datos
Xianyong Bu	Senior Vice President	no data	sin datos	sin datos
Rongqiang Liu	Senior Vice President	1.5yrs	sin datos	sin datos

3.1yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1873 se considera experimentado (3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Chen Cheney Mao	Chairman & CEO	5.8yrs	CN¥2.76m	8.65% CN¥ 114.9m
Ying Wu	Executive VP & Executive Director	14.7yrs	CN¥3.07m	0.80% CN¥ 10.7m
Delin Ren	Executive Director	5.8yrs	CN¥3.72m	0.69% CN¥ 9.2m
Haiguang Wang	Independent Non-Executive Director	5.1yrs	CN¥216.00k	sin datos
Lei Fu	Independent Non-Executive Director	5.1yrs	CN¥216.00k	sin datos
Xiangrong Li	Independent Non-Executive Director	5.1yrs	CN¥216.00k	sin datos
Yuting Wu	Non-Executive Director	1.5yrs	CN¥30.00k	sin datos
Hui Wang	Non-Executive Director	less than a year	sin datos	3.97% CN¥ 52.7m

5.1yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 1873 se considera experimentada (5 años de antigüedad promedio).

Viva Biotech Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

Executive VP & Executive Director recently bought HK$226k worth of stock

Less than half of directors are independent

Recent updates

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

New 90-day low: HK$6.90

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

New 90-day low: HK$7.27

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Viva Biotech Holdings Announces Resignation of MAO Jun as Non-Executive Director

New 90-day low: HK$7.38

Executive Director & CFO recently bought HK$7.0m worth of stock

New 90-day low: HK$8.18